Biomarker utility in Alzheimer's disease clinical trials

Cerebrospinal fluid, imaging and blood based biomarkers can provide critical information for dose selection, patient enrichment and supplementary evidence of disease modification in current clinical trials testing experimental therapeutics for Alzheimer's disease (AD). The current treatise provides examples of biomarker strategies utilized in AD clinical trial practice and highlights recent advances towards the identification of non-invasive approaches for enrichment and diagnosis.